BREAKING NEWS: Pembrolizumab (KEYTRUDA) immunotherapy has been approved for MSI-HIGH CRC!!!
The title says it all, although it should also be noted that this approval also covers other/all MSI-high cancers, not just MSI-HIGH CRC!. Links below. The first time a checkpoint immunotherpy (pembrolizumab (Keytruda)) is a PD1 inhibitor Immunotherapy) has been approved based upon a genetic marker (in this case MSI-Status – something I first described here back in 2015! (Stephen profiled in that 2015 article continues to do awesome by the way with no evidence of disease!)
It should be noted that only 15-20% of cases of CRC are MSI-high (and only about 5% of Stage IV patients) but we are all apart of the CRC family and indeed a part of the overall Stage IV family no matter what the ribbon color!
I am beyond ecstatic for me MSI-high CRC brother and sisters! I have been 100% sure this approval would happens due to the continuous wave of success stories in the patient message boards and online communities – it has just been a question of not if, not WHEN. And today that when happened!!
THIS IS WHY IT IS SO IMPORTANT FOR ALL CRC PATIENTS TO KNOW THEIR MSI STATUS!!!
Here are the links: